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Assessment of the predictive value of p53 requires the testing of large numbers of samples from patients enrolled in
prospective phase III clinical trials. The goal of this study was to determine whether p53 status can be determined by p53
yeast functional assay using the limiting amounts of material that can typically be obtained in prospective phase III trials
(particularly when chemotherapy is given before surgery). All patients presenting with a clinically palpable tumour which could
be considered large enough to perform a trucut biopsy (52 cm breast tumour) were eligible for this study. Two trucut
biopsies and one incisional biopsy were performed on the surgical specimens (mastectomy or tumourectomy). Samples were
snap frozen and cryostat sections were taken for histology and p53 testing. Thirty patients were included. Three samples out
of 90 failed to give any p53 PCR products, probably because these samples contained almost entirely ﬁbrous tissue. Of the 87
samples that could be tested, the incisional and trucut biopsies results were fully concordant in every case. p53 could be
deﬁned in 97% of patients by double trucut biopsy. Eight out of 30 tumours tested were mutant for p53 (27%). p53 status
can be reliably determined by yeast assay from single frozen sections of trucut biopsies. Histological examination before p53
testing is essential to exclude cases where the p53 result may reﬂect only the status of the normal cells in the biopsy.
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Experimental and clinical studies have shown that anticancer agents
strongly induce apoptosis (Hickman, 1992; Ellis et al, 1997). p53 is
a key regulatory gene in the apoptotic pathway, and experimental
data have shown that tumours containing wild type p53 respond
better to anthracyclines than p53-mutant tumours (Lowe et al,
1993, 1994; Gudas et al, 1996). In contrast, most in vitro and in
vivo studies have shown that p53 status does not affect the response
to taxanes (Woods et al, 1995; Brown, 1996; Jordan et al, 1996;
Perego et al, 1996; Wahl et al, 1996; Lanni et al, 1997; O’Connor
et al, 1997; Fan et al, 1998).
Taken together, these experimental results suggest that p53
status may help to predict the response to chemotherapy with
anthracyclines or taxanes in clinical practice. Speciﬁcally, one can
make the hypothesis that p53 mutant tumours will be anthracy-
cline-resistant but taxane-sensitive. Several clinical studies
addressing this question have failed to demonstrate a predictive
value of p53. Two clinical studies where the p53 DNA sequence
was assessed suggested that p53 status may be important. The ﬁrst
study found that p53 mutant tumours were resistant to anthracy-
clines (Aas et al, 1996) and the second found that p53 mutant
tumours were sensitive to taxanes (Kandioler-Eckersberger et al,
2000). However the number of patients analysed in these studies
was too small for deﬁnitive conclusions to be drawn.
In order to address this question deﬁnitively in breast cancer we
have initiated a large phase III clinical trial (EORTC 10994/BIG 00-
01 study). Testing p53 in the context of a phase III clinical trial
poses major technical and logistical problems which deserve
comment. First, correlation of a single biological variable with
response to different treatments, the minimum design to show a
predictive effect, requires four times as many patients as a standard
two treatment comparison (Peterson and George, 1993). Making
reasonable assumptions about the likely prognostic and treatment
effects of p53 status in patients with locally advanced breast cancer,
the number of patients required to answer the p53/taxane question
in 3 years is about 1400. Second, although widely available, immu-
nohistochemistry (IHC) is not the best method to assess p53 status.
The risk of false-positive and false-negative results is higher with
IHC than sequencing (Fisher et al, 1994; Sjogren et al, 1996; Duddy
et al, 2000). In particular, IHC fails to detect mutants which
encode unstable proteins (nonsense mutations, splicing mutations),
which have been found in up to 47% of p53 mutations in breast
tumours (Chappuis et al, 1999). Simpler DNA structure-based
techniques, particularly denaturing gradient gel electrophoresis,
are sensitive but require sequencing to show that the change is
not a polymorphism or silent mutation. Genomic p53 sequencing
is generally considered to be the gold standard against which
new p53 assessment methods should be compared, but complete
detection of mutations in formalin ﬁxed tissue requires microdis-
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www.bjcancer.comsection of tumour samples, a time-consuming procedure when
hundreds of samples must be tested (Hartmann et al, 1997). We
have pioneered the use of an RNA-based technique that detects
functionally important p53 mutations (Flaman et al, 1995). We
amplify p53 cDNA by RT–PCR and then express the cloned
DNA in yeast. If the encoded p53 protein is wild type it activates
transcription of a reporter gene. The advantage of this technique is
that it tests a large number of individual clones, so it can detect
mutant p53 mRNA in clinical samples that contain a substantial
amount of normal tissue. It is also possible to test the large
number of samples required to answer clinical questions, such as
the role of p53 in taxane response. Although nonsense-mediated
RNA decay renders detection of chain-terminating mutations more
difﬁcult with an RNA-based technique, we have shown that the
yeast assay is particularly good at detecting this type of mutation
(Chappuis et al, 1999). Third, collection of samples in a manner
that preserves the integrity of RNA is a major problem in a multi-
centre clinical trial. We have previously shown that p53 status can
be accurately determined from frozen sections of incisional biopsies
from breast tumours (Chappuis et al, 1999). Patients presenting
with large operable or locally-advanced/inﬂammatory breast
cancers will be eligible to participate in the EORTC 10994/BIG
00-01 study. Current practice in this group of patients is to use
trucut biopsies rather than incisional biopsies. The purpose of
the present study was to determine whether it is feasible to test
the p53 status of breast tumours by yeast assay in conditions
resembling those pertaining in this EORTC clinical trial.
MATERIALS AND METHODS
Permission for the study was granted by the Geneva University
Hospitals ethics committee. All patients gave informed consent
to participate in the study. Mastectomy or tumourectomy speci-
mens in a group of 30 patients were taken from the operating
theatre to the pathology department with the minimum delay
and three biopsies were taken (two trucut biopsies with a 14G
needle and one incisional biopsy). The study was performed
on surgically resected mastectomy or tumourectomy specimens
because ethical concerns preclude multiple sampling of tumours
for research purposes in living subjects. Biopsies were embedded
in OCT and frozen in 2-methylbutane immediately. Samples for
routine diagnosis were taken in parallel and ﬁxed in formalin.
Histological assessment of all samples was performed by the
same pathologist (MF Pelte). The yeast assay was performed
on 100 mm frozen sections essentially as described by Chappuis
et al (1999). mRNA was puriﬁed using oligo-dT Dynabeads
(Dynal). Total RNA was puriﬁed with Trizol (Life Technologies).
Pfu turbo polymerase (Stratagene) was used instead of Pfu poly-
merase. To rule out a decrease in ﬁdelity of this enzyme induced
by the proprietary modiﬁcation, we performed polymerase ﬁde-
lity assays (Flaman et al, 1994). Consistent with the
manufacturer’s claims, we could detect no difference in the ﬁde-
lity of Pfu and Pfu turbo (data not shown). We therefore used
Pfu turbo for the present study. The greater processivity meant
that a 1 kb p53 cDNA fragment could be ampliﬁed as efﬁciently
as the smaller fragments used for the split version of the yeast
assay (Waridel et al, 1997). We therefore used only the conven-
tional form of the assay, in which a 1 kb p53 PCR product is
gap repaired into the pRDI-22 yeast expression vector (Waridel
et al, 1997).
Sequencing was performed on a minimum of four plasmids
rescued from different colonies for each p53 mutant tumour.
Sequencing primers were either IF12 and IR13 (Chappuis et al,
1999) or IF216 and IR217 (Table 1), which lie at the beginning
and end of the p53 open reading frame and permit sequencing
of the entire open reading frame in a single run on a Licor
4200L sequencer. Each plasmid was sequenced on only one strand,
but each mutation was visualised on both strands.
To test sample 17B by microdissection, a single frozen section
was dissected with a Leica laser microdissector. Genomic DNA
was extracted by proteinase K digestion, ampliﬁed by nested PCR
and exons 4–7 were sequenced directly (see Table 1 for primers).
Quantitative PCR for GAPDH was performed on a PE5700 PCR
machine using primers gaaggtgaaggtcggagtc, gaagatggtgatgggatttc,
and Taqman probe caagcttcccgttctcagcc. cDNA was synthesised
with Superscript reverse transcriptase (Life Technologies) as for
p53 (Chappuis et al, 1999) except that hexamers were used, and
ampliﬁed using a Taqman PCR master mix (Perkin-Elmer).
RESULTS
Deﬁnition of the cut-off for assignment of p53 status
One critical parameter in the test is the background number of red
colonies. This determines the maximum permissible contamination
of tumour samples with genetically normal cells. Histological
examination revealed that most samples contained little or no
normal breast tissue, but all contained signiﬁcant numbers of
genetically normal cells, principally ﬁbroblasts, inﬂammatory cells
and endothelial cells. Samples frequently contained large ﬁbrotic
acellular regions, with tumour cells present in small islands. Precise
estimation of the number or fraction of tumour cells is extremely
difﬁcult in such heterogeneous material. The observed distribution
of red colonies was used to infer the real background with clinical
samples. The causes of variation in the background include factors
like RNA polymerase errors, splicing artefacts, reverse transcriptase
errors, Pfu polymerase errors, variation in the amount of input
RNA, gap repair cloning artefacts, recombination at the reporter
locus and yeast genetic suppressors of leu2-3,112. If we assume that
these occur essentially at random, we should see two superimposed
distributions in the results: a normally distributed population
derived from wild type samples, superimposed upon a ﬂatter distri-
bution derived from p53 mutant samples. The latter can take any
value above background, depending on the amount of normal
tissue in the sample. This is exactly what is observed. Figure 1
shows the distribution of all results from this study combined with
those of Chappuis et al (1999), which was also performed on
frozen sections of breast tumours. Since we know from sequencing
of plasmids rescued from red colonies that samples with 520%
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Table 1 PCR and sequencing primers
p53 genomic PCR primers
Ex 4 sense outer ATGGGACTGACTTTCTGCTCTTGT
Ex 4 anti outer GATGGATAAAAGCCCAAATTCAA
Ex 4 sense nested CTGGTAAGGACAAGGGTTGG
Ex 4 anti nested GCCTAAGGGTGAAGAGGAATC
Ex 5-6 sense outer CTCCTGAGGTGTAGACGCCAAC
Ex 5-6 anti outer CCCATTTACTTTGCACATCTCATG
Ex 5-6 sense nested GCTCGCTAGTGGGTTGCAGGA
Ex 5-6 anti nested GGAGGTCAAATAAGCAGCAGGAGAA
Ex 7 sense outer AGCTTGCAGTGAGCTGAGATCA
Ex 7 anti outer AAAAGGAAACTGAGTGGGAGCA
Ex 7 sense nested CGACAGAGCGAGATTCCATCT
Ex 7 anti nested GCCGGAAATGTGATGAGAGGT
Sequencing primers
IR223 Ex 4 sense AAGGACAAGGGTTGGGCTG
IF224 Ex 4 anti CCCAAAGTTCCAAACAAAAG
IR219 Ex 5-6 sense TTCTTTGCTGCCGTGTTC
IF210 Ex 5-6 anti AAGCAGCAGGAGAAAGC
IR225 Ex 7 sense TTGCCACAGGTCTCCCCAAG
IF226 Ex 7 anti GAAGAAATCGGTAAGAGGTGG
IF216 p53 5' cDNA CCTCTGAGTCAGGAAAC
IR217 p53 3' cDNA GTGGAGAATGTCAGTCTGAG
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 750–755red colonies contain clonal mutations, we can disregard these
samples and calculate the mean and standard deviation of the
remaining samples to obtain an upper limit for the background.
The mean is 5%, with a standard deviation of 3%. This value
for the standard deviation probably slightly overestimates the true
variation because the wild type and mutant distributions overlap.
p53 status determined by yeast assay
Eight out of 30 tumours tested were mutant for p53 (27%, Table
2). Three samples failed to give any p53 PCR products. Histological
examination revealed that these samples contained almost entirely
ﬁbrous tissue with very few cells. Of the samples that could be
tested, the incisional and core biopsy results were fully concordant
in every case (520% or 520% red colonies) except for HB12,
HB18 and HB27, where the percentage of red colonies was between
10 and 19%. Sequencing of plasmids rescued from red colonies
revealed that the 187fs mutation was present in the red colonies
from all three HB12 samples (B, TC1, TC2), that the 266E muta-
tion was present in all three HB18 samples (B, TC1, TC2) and that
the 278S mutation was present in all three HB27 samples (B, TC1,
TC2). The low percentage of red colonies in the discordant samples
was thus due to a low tumour cell content, rather than a high
background intrinsic to the assay. Plasmids were rescued from
red colonies in every other case where the mutant content was
520%. The same mutation was found in every sample from a
given tumour, again conﬁrming that the use of frozen sections of
biopsies is perfectly compatible with assignment of p53 status by
yeast functional assay.
The analysis above was performed with mRNA puriﬁed on
paramagnetic beads. Since mRNA puriﬁcation is extremely sensi-
tive to RNA quality, we retested 54 samples for which material
was available using total RNA (Table 2). The yield of RNA
measured by a quantitative PCR assay for GAPDH was higher
with total than messenger RNA (median 27-fold, interquartile
range 7.6- to 101-fold), suggesting that RNA degradation may
indeed be a problem in the biopsies. Except for HB12 TC2 and
HB27 TC2, the assignment of p53 status was identical using
mRNA and total RNA, and the background was the same. Both
HB12 and HB27 contain mutant p53, but in one case the percen-
tage red colonies fell below the 20% cut-off and in the other it
rose above it. This is most likely explained by changes in the
mutant content at different levels in the biopsy. Other groups
have also obtained satisfactory results with the yeast assay using
total RNA extracted from tumours (Tada et al, 1996; Kashiwazaki
et al, 1997; Obata et al, 2000).
Mutation type
The base changes are given in Table 3. Only three of the eight p53
mutations identiﬁed were classic missense mutations. The remain-
der were frameshift mutations. This is an unusually high
proportion of frameshifts, compared to the data in the literature
(IARC database, Hernandez-Boussard et al, 1999). This high
proportion may be due to chance in this small series or to the fact,
as we previously noted, that the yeast assay is particularly good at
detecting non-missense mutations (Chappuis et al, 1999). Several
arguments point to the mutations being real. First, the same muta-
tion was present in three different samples (the incisional biopsy
and two trucut biopsies). Second, we retested one biopsy from four
of the ﬁve patients with frameshift mutations and conﬁrmed the
result (HB2, HB9, HB12, HB17; in HB11 there was insufﬁcient
material for retesting) (Table 2). The exact percentage of red was
not the same on retesting because the mutant content varies at
different levels in the biopsy. In HB12 TC2 the percentage of red
was below the 20% cut-off, but the same mutation was identiﬁed
by sequencing of plasmids rescued from red yeast colonies on both
occasions. Third as a direct test of whether we could conﬁrm the
presence of the mutation in HB17, we directly sequenced DNA
extracted from a laser microdissected section. This showed that
the same mutation was present in the genomic DNA as in the
cDNA (Figure 2). There was insufﬁcient material to test the other
samples containing frameshift mutations by microdissection. Taken
together, these results make it unlikely that the frameshift muta-
tions were caused by some hidden artefact in the yeast assay.
DISCUSSION
The main conclusion from this study is that it is possible to test
the p53 status of trucut biopsies of breast tumours using a func-
tional assay in yeast. Ninety samples were taken and the yeast
assay was successfully performed on 87 of them. In three patients
the functional assay failed completely with one of the trucut biop-
sies, but was successful with the other. Complete failure, meaning
we were unable to amplify an RT–PCR product, is most likely due
to a combination of RNA degradation and low cellularity of the
sample.
The commonest problem was not failure to obtain RNA but a
low tumour cell content. It clearly makes no sense to assign a
p53 status to samples containing only very small numbers of
tumour cells, because of the very substantial risk that the result
reﬂects only the status of the normal cells in the biopsy. For this
reason it is essential that a trained pathologist examines samples
histologically and excludes those samples with less than a mini-
mum threshold amount of tumour cells. The choice of this
threshold is arbitrary, but since we use a 20% red colony cut-off
for assignment of p53 status in the yeast assay (see below), it would
be reasonable to exclude samples containing less than 20% tumour
cells on histological examination. In one case (HB9 TC2), the
percentage of red colonies was much higher than the tumour cell
content (50 vs 5%). Finding a somewhat higher percentage of
red colonies than percentage of tumour cell content is normal
given the higher rate of transcription in metabolically active
tumour cells than normal cells, but a 10-fold difference is unusual.
The most likely explanation in HB9 TC2 is that the tumour cell
content was higher in the section tested by yeast assay than in
the section processed for histology.
The distribution of values for ostensibly wild type samples was
used to estimate the background in the assay. The true background
should be slightly lower, because some putative wild type samples
may have contained low numbers of p53 mutant tumour cells. By
selecting a cut-off of 20% red colonies for the prospective clinical
trial mentioned in the introduction (EORTC 10994/BIG 00-01
study), we expect to correctly identify all tumours containing wild
type p53 (high speciﬁcity). A small number of p53 mutant samples
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Figure 1 Histogram showing the distribution of the percentage of red
for yeast assays on frozen sections of breast tumours. The mean back-
ground with wild type samples is 5% red colonies (see text).
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there is a good chance, as shown with HB9, HB18 and HB27, that
in these cases the second biopsy will contain more tumour cells
and give a positive result.
The p53 status assigned (wild type or mutated) was identical
whether we used material from trucut biopsies or incisional biop-
sies, except for three patients where the assay gave values below the
20% red colony threshold with one sample, but a mutant value
with the other two samples. These results are most likely due to
heterogeneity in the biopsies themselves, rather than any defect
in the assay. This heterogeneity can take the form of either varia-
tion in tumour genotype or variation in tumour content in the
biopsy. Eleven samples taken by trucut biopsy should have been
excluded (RT–PCR failure in three cases, 520% tumour cells in
eight cases). However in all these tumours the p53 status could
be assessed using the second trucut. When we designed this study
we were concerned with the fact that with trucut biopsies the
physician is unable to conﬁrm visually that actual tumour has been
sampled. Even correct placement of the needle within the tumour
mass does not guarantee that the sample will contain viable
tumour cells, because tumours contain large areas of necrotic
and ﬁbrotic material. To address these concerns, we decided in this
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Table 2 p53 status assessed by yeast assay comparing incisional (B) and trucut biopsies (TC1 and TC2) from the same
tumour
% % Red % Red % % Red % Red
Tumour colonies colonies p53 Tumour colonies colonies p53
Sample cells mRNA total RNA status Sample cells mRNA total RNA status
HB1 B 40 3 6 wt HB16 B 90 4 0 wt
TC1 40 6 6 wt TC1 90 2 wt
TC2 30 3 3 wt TC2 90 5 9 wt
HB2 B 50 54 mut HB17 B 90 65 mut
TC1 50 32 mut TC1 90 24/44 mut
TC2 30 29/30 30 mut TC2 80 47 55 mut
HB3 B 50 4 wt HB18 B 50 40 mut
TC1 50 6 4 wt TC1 10 16 (mut)
TC2 50 5 5 wt TC2 30 26 wt
HB4 B 90 5 3 wt HB19 B 80 1 wt
TC1 90 4 6 wt TC1 60 5 5 wt
TC2 80 5 4 wt TC2 75 5 3 wt
HB5 B 50 7 3 wt HB20 B 80 3 3 wt
TC1 0 8 wt TC1 75 4 3 wt
TC2 40 4 2 wt TC2 80 5 3 wt
HB6 B 30 5 3 wt HB21 B 80 3 2 wt
TC1 30 7 5 wt TC1 90 1 4 wt
TC2 5 10 wt TC2 90 8 7 wt
HB7 B 80 4 wt HB22 B 50 1 wt
TC1 90 3 5 wt TC1 40 2 4 wt
TC2 70 7 4 wt TC2 60 3 3 wt
HB8 B 50 3 2 wt HB23 B 90 4 3 wt
TC1 40 failure failure TC1 90 4 6 wt
TC2 0 2 6 wt TC2 75 2 wt
HB9 B 80 46 mut HB24 B 75 3 3 wt
TC1 50 53 mut TC1 80 3 7 wt
TC2 5 55/50 mut TC2 90 2 2 wt
HB10 B 50 3 wt HB25 B 90 30 mut
TC1 50 6 wt TC1 80 53 37 mut
TC2 10 failure failure TC2 40 38 mut
HB11 B 60 30 mut HB26 B 90 5 wt
TC1 80 45 mut TC1 80 6 2 wt
TC2 90 34 mut TC2 90 5 5 wt
HB12 B 75 14/18 14 (mut) HB27 B 80 47 40 mut
TC1 80 39 mut TC1 70 32 34 mut
TC2 80 41 14 mut TC2 5 14 26 (mut)
HB13 B 90 3 wt HB28 B 75 3 4 wt
TC1 90 6 wt TC1 75 2 3 wt
TC2 90 3 wt TC2 75 5 wt
HB14 B 90 4 2 wt HB29 B 50 2 3 wt
TC1 90 12 2 wt TC1 60 3 7 wt
TC2 80 4 wt TC2 10 2 3 wt
HB15 B 5 7 2 wt HB30 B 15 2 3 wt
TC1 90 5 wt TC1 50 2 5 wt
TC2 90 failure failure TC2 15 6 5 wt
Where p53 status is given as (mut) the per cent of red falls below the 20% threshold for assignment as mutant but the sample was shown to
contain the same mutation as the other biopsies from that patient by sequencing of plasmids rescued from red colonies. Where two values are
given for a per cent red, the results were obtained from different sections (these samples were retested because the mutations identiﬁed were
frameshifts).
p53 function and response to chemotherapy
H Bonnefoi et al
753
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 750–755pilot study to take two trucut biopsies from each patient. This
doubles the amount of work involved but the results obtained have
vindicated this decision. Three samples taken by incisional biopsy
gave less than 20% tumour cells and should have been excluded.
Overall, if the 20% cut-off for tumour cell content and 20% cut-
off for red colonies is applied, p53 status could be deﬁned in
90% of patients by single incisional biopsy and 97% of patients
by double trucut biopsy.
In conclusion we have shown in this study that p53 status can
reliably be assigned by yeast assay using two trucut biopsies from
the same tumour instead of a single incisional biopsy. Use of trucut
biopsies will facilitate inclusion of patients in the EORTC 10994/
BIG 00-01 clinical trial of neoadjuvant chemotherapy prior to
surgery. This pilot study underlined the importance of performing
histological examination before p53 testing in order to exclude
cases where the p53 result may reﬂect only the status of the normal
cells in the biopsy. In the EORTC 10994/BIG 00-01 trial a cryostat
section of every biopsy will be examined histologically and only
cases with 20% or more of tumour cells will be included in the
study. To determine whether p53 status can more accurately be
determined by chip techniques, a subset of samples from this study
will also be tested on microarrays.
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Table 3 p53 mutations identiﬁed by sequencing of plasmids rescued
from red yeast colonies
Mutant
Sequencing from cDNA
Sample codon
a,b Base change Exon
HB2 B 91fs (2/2)
TC1 91fs (1/1) 273, deletion of 2 bp 4
TC2 91fs (2/2) TGGCCCCTG?TGCCCTG
HB9 B 178fs (2/3)
TC1 178fs (4/4) 533, insertion of 1 bp 5
TC2 178fs (4/4) TGCCCCCA?TGCCCCCA
HB11 B 236fs (3/3)
TC1 236fs (1/1) 707, insertion of 1 bp 7
TC2 236fs (3/3) TAC?TAAC
HB12 B 187fs (5/7)
TC1 187fs (1/1) 560, deletion of 1 bp 5/6 splice site
TC2 187fs (1/1) TGGTCT?TGTCTG
HB17 B 112fs (1/1)
TC1 112fs (3/3) 336, deletion of 2 bp (CT) 4
TC2 112fs (1/1) GGGCTTCT?GGGTCTT
HB18 B 266E (1/1)
TC1 266E (1/1) 796, point missense mutation 8
TC2 266E (1/1) GGA?GAA (Gly to Glu)
HB25 B 213Q (2/2)
TC1 213Q (1/1) 638, point missense mutation 6
TC2 213Q (1/1) CGA?CAA (Arg to Gln)
HB27 B 278S (2/2)
TC1 278S (1/1) 832, point missense mutation 8
TC2 278S (1/1) CCT?TCT (Pro to Ser)
aThe codon indicated is the ﬁrst abnormal codon.
bThe second number in brackets
indicates the number of red colonies tested and the ﬁrst number indicates the
number of red colonies where the mutation was shown. Example: 178fs (2/3) the
mutant codon was identiﬁed in two out of three different red colonies.
}
}
}
}
}
}
}
}
genomic
cDNA
Figure 2 Genomic and cDNA sequence showing the mutation in sam-
ple 17B.
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